CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment

[1]  À. Rovira,et al.  Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. , 2015, Brain : a journal of neurology.

[2]  J. Frederiksen,et al.  Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis , 2015, Multiple sclerosis.

[3]  K. Blennow,et al.  CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment , 2014, Journal of Neuroimmunology.

[4]  I. Melle,et al.  Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta‐analysis , 2013, Acta psychiatrica Scandinavica.

[5]  L. Schlichter,et al.  The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion , 2013, Journal of Neuroinflammation.

[6]  M. Landén,et al.  The societal cost of bipolar disorder in Sweden , 2013, Social Psychiatry and Psychiatric Epidemiology.

[7]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[8]  D. Kupfer,et al.  Bipolar disorder diagnosis: challenges and future directions , 2013, The Lancet.

[9]  K. Blennow,et al.  Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder , 2013, Neuropsychopharmacology.

[10]  C. Ekman,et al.  Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls , 2012, BMC Psychiatry.

[11]  M. Portella,et al.  Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study , 2012, Psychological Medicine.

[12]  K. Blennow,et al.  Biomarkers for Microglial Activation in Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[13]  Michael F. Green,et al.  The impact of neurocognitive impairment on occupational recovery of clinically stable patients with bipolar disorder: a prospective study , 2011, Bipolar disorders.

[14]  R. Kessler,et al.  Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. , 2011, Archives of general psychiatry.

[15]  M. Berk,et al.  eview athways underlying neuroprogression in bipolar disorder : Focus on nflammation , oxidative stress and neurotrophic factors , 2010 .

[16]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[17]  S. Sakoda,et al.  Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors , 2010, European journal of neurology.

[18]  S. Rapoport,et al.  Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients , 2010, Molecular Psychiatry.

[19]  À. Rovira,et al.  Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.

[20]  Klaus P. Ebmeier,et al.  Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. , 2009, The British journal of psychiatry : the journal of mental science.

[21]  M. Thase,et al.  A history of childhood attention‐deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD , 2009, Acta psychiatrica Scandinavica.

[22]  R. McIntyre,et al.  Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. , 2009, The Journal of clinical psychiatry.

[23]  E. Bora,et al.  Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. , 2009, Journal of affective disorders.

[24]  M. Portella,et al.  Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. , 2008, The Journal of clinical psychiatry.

[25]  Tiao-Lai Huang,et al.  High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  W. Scheper,et al.  The significance of neuroinflammation in understanding Alzheimer’s disease , 2006, Journal of Neural Transmission.

[27]  Peter Gallagher,et al.  A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. , 2006, Journal of affective disorders.

[28]  I. Ferrier,et al.  Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. , 2006, Bipolar disorders.

[29]  H. Ling,et al.  Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes* , 2005, Journal of Biological Chemistry.

[30]  B. Maier,et al.  Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. , 2005, Journal of neurotrauma.

[31]  J. Savitz,et al.  Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. , 2005, Bipolar disorders.

[32]  A. H. Berman,et al.  Evaluation of the Drug Use Disorders Identification Test (DUDIT) in Criminal Justice and Detoxification Settings and in a Swedish Population Sample , 2004, European Addiction Research.

[33]  D. Kupfer,et al.  Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) , 2003, Biological Psychiatry.

[34]  S. Lorenzl,et al.  Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.

[35]  G. Devercelli,et al.  Health care utilization and costs among privately insured patients with bipolar I disorder. , 2002, Bipolar disorders.

[36]  J. Lundgren,et al.  YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis , 2002, Clinical and Vaccine Immunology.

[37]  J. Johansen,et al.  Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. , 1999, Rheumatology.

[38]  O. Aasland,et al.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. , 1993, Addiction.

[39]  D. Mackinnon,et al.  Estimating Mediated Effects in Prevention Studies , 1993 .

[40]  Henrik Zetterberg,et al.  Cerebrospinal fluid biomarkers mirror rate of cognitive decline. , 2013, Journal of Alzheimer's disease : JAD.

[41]  K. Blennow,et al.  Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. , 2011, Journal of Alzheimer's disease : JAD.

[42]  K. Blennow,et al.  Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[43]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[44]  Kenneth J Sher,et al.  The development of alcohol use disorders. , 2005, Annual review of clinical psychology.

[45]  A. Muijsers,et al.  Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. , 1998, European journal of biochemistry.

[46]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[47]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[48]  K. Blennow,et al.  Journal of Central Nervous System Disease , 2022 .